Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-κB-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells by Philip, Subha et al.
Osteopontin Stimulates Tumor Growth and Activation of
Promatrix Metalloproteinase-2 through Nuclear Factor-B-mediated
Induction of Membrane Type 1 Matrix Metalloproteinase in
Murine Melanoma Cells*
Received for publication, April 13, 2001, and in revised form, September 17, 2001
Published, JBC Papers in Press, September 19, 2001, DOI 10.1074/jbc.M103334200
Subha Philip, Anuradha Bulbule, and Gopal C. Kundu‡
From the National Center for Cell Science, NCCS Complex, Pune 411 007, India
Matrix metalloproteinases (MMPs) degrade the extra-
cellular matrix (ECM) and play critical roles in tissue
repair, tumor invasion, and metastasis. MMPs are regu-
lated by different cytokines, ECM proteins, and other
factors. However, the molecular mechanisms by which
osteopontin (OPN), an ECM protein, regulates ECM in-
vasion and tumor growth and modulates MMP activa-
tion in B16F10 cells are not well defined. We have puri-
fied OPN from human milk and shown that OPN induces
pro-MMP-2 production and activation in these cells.
Moreover, our data revealed that OPN-induced mem-
brane type 1 (MT1) MMP expression correlates with
translocation of p65 (nuclear factor-B (NF-B)) into the
nucleus. However, when the super-repressor form of
IB (inhibitor of NF-B) was transfected into cells fol-
lowed by treatment with OPN, no induction of MT1-
MMP expression was observed, indicating that OPN ac-
tivates pro-MMP-2 via an NF-B-mediated pathway.
OPN also enhanced cell migration and ECM invasion by
interacting with v3 integrin, but these effects were
reduced drastically when the MMP-2-specific antisense
S-oligonucleotide was used to suppress MMP-2 expres-
sion. Interestingly, when the OPN-treated cells were in-
jected into nude mice, the mice developed larger tu-
mors, and the MMP-2 levels in the tumors were
significantly higher than in controls. The proliferation
data indicate that OPN increases the growth rate in
these cells. Both tumor size and MMP-2 expression were
reduced dramatically when anti-MMP-2 antibody or an-
tisense S-oligonucleotide-transfected cells were injected
into the nude mice. To our knowledge, this is the first
report that MMP-2 plays a direct role in OPN-induced
cell migration, invasion, and tumor growth and that
demonstrates that OPN-stimulated MMP-2 activation
occurs through NF-B-mediated induction of MT1-MMP.
Cell migration and extracellular matrix invasion are some of
the major steps in embryonic development (1, 2) and wound
healing and cancer cell metastasis (3, 4). However, the exact
molecular mechanisms that regulate these processes are not
well understood. In the past, several investigators have shown
that matrix metalloproteinases (MMPs)1 and the tissue inhib-
itor of matrix metalloproteinase (TIMP) play a major role in the
regulation of cancer cell migration, extracellular matrix (ECM)
invasion, and metastasis by degrading the ECM proteins (3–5).
Current investigations have focused on the understanding of
molecular mechanism(s) by which osteopontin (OPN), an ECM
protein, regulates MMP expression both in vitro and in vivo
and controls invasiveness and tumor growth in B16F10 cells.
OPN is a noncollagenous, sialic acid-rich, and glycosylated
phosphoprotein (6, 7). It has an N-terminal signal sequence, a
highly acidic region consisting of nine consecutive aspartic acid
residues, and a GRGDS cell adhesion sequence predicted to be
flanked by the -sheet structure (8). This protein has a func-
tional thrombin cleavage site and is a substrate for tissue
transglutaminase (7). OPN binds with type I collagen (9), fi-
bronectin (10), and osteocalcin (11). Several highly metastatic
transformed cells synthesize higher levels of OPN compared
with non-tumorigenic cells (12). It has been shown that OPN
also interacts with CD44 receptor globulin (13). OPN causes
cell adhesion and migration, ECM invasion, and cell prolifera-
tion by interacting with its receptor v3 integrin in various
cell types (14). Integrins are noncovalently associated, het-
erodimeric, cell-surface glycoproteins with - and -subunits.
Integrins are a superfamily of transmembrane glycoproteins
found predominantly on the surface of leukocytes that mediate
cell-cell and cell-substratum interactions. Until today, 12
-subunits, 8 -subunits, and 20 -heterodimers were docu-
mented in the literature (15).
MMPs are a family of enzymes that are classified under
different subgroups (16). MMP-2 (also called type IV collagen-
ase or gelatinase A) degrades several ECM proteins such as
fibronectin, laminin, type I collagen, and proteoglycans. It
plays critical roles in embryogenesis, tissue remodeling, in-
flammation, periodontitis, and metastasis (16). Several reports
have indicated that the increased levels of MMP-2 correlate
with the invasive properties of certain tumor cell types (16, 17).
TIMP-2 is the specific inhibitor of MMP-2. TIMP-2 is a non-
glycosylated protein (21 kDa) that forms a complex with both
the inactive and active forms of MMP-2 (18).
Previous studies have demonstrated that the ligation of v3
integrin in melanoma cells by anti-v3 integrin antibodies
enhances the expression of MMP-2, resulting in increased lev-
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els of cellular invasiveness (17). Furthermore, treatment of
melanoma cells with vitronectin induces the expression of
MMP-2 and TIMP-2 as well as enhances cellular invasiveness
in a dose-dependent manner (19). Takahashi et al. (20) showed
that treatment of human melanoma cells with monoclonal anti-
CD44 antibody induced the expression of MMP-2 and enhances
cell migration and ECM invasion. However, treatment of the
same melanoma cells with recombinant OPN-glutathione S-
transferase fusion protein failed to induce the expression of
MMP-2. It was speculated that MMP-2 expression did not occur
probably because of the glutathione S-transferase fusion with
osteopontin (20). Recently, Maquoi et al. (21) have shown that
type IV collagen induces the activation of MMP-2 in human
fibrosarcoma cells.
Here we report that treatment of B16F10 cells with purified
human OPN (but not with other ECM proteins such as fi-
bronectin, type I collagen, and laminin) induced the expression
of pro-MMP-2 and active MMP-2. We provide evidence that
OPN induced membrane type 1 (MT1) MMP expression by
stimulating the nuclear factor-B (NF-B) pathway. OPN also
enhanced cell migration and ECM invasion by interacting with
the v3 integrin receptor in these cells. Transient transfection
of B16F10 cells with the MMP-2-specific antisense S-oligonu-
cleotide (ASMMP-2), but not with the sense S-oligonucleotide
(SMMP-2), caused pronounced inhibition of MMP-2 protein
expression and drastic suppression of OPN-induced cell migra-
tion and ECM invasion. Interestingly, OPN also induced tumor
growth, and expression of MMP-2 in tumors of OPN-injected
nude mice was significantly higher than in controls. Moreover,
when anti-MMP-2 antibody was injected into OPN-induced
tumors, the size of the tumors and the levels of active MMP-2
were reduced dramatically compared with controls. Similarly,
when ASMMP-2-transfected cells were injected into the mice,
the size of the tumors and the levels of MMP-2 were also
suppressed compared with SMMP-2- or LipofectAMINE Plus-
injected cells. Taken together, these data indicate that OPN-
induces pro-MMP-2 expression and activation and enhances
cell migration, ECM invasion, and tumor growth. These data
further demonstrate that MMP-2 is mechanistically involved in
the regulation of these processes.
EXPERIMENTAL PROCEDURES
Materials—Fibronectin, type I collagen, laminin, GRGDSP, GPen-
GRGDSPCA, GRGESP, and LipofectAMINE Plus reagent were pur-
chased from Life Technologies, Inc. Mouse monoclonal anti-MMP-2
(Ab-3) and anti-MT1-MMP antibodies were obtained from Oncogene
Research. Rabbit anti-human v3 integrin antibody was from Chemi-
con International. Goat anti-human v integrin, mouse monoclonal
anti-3 integrin, and rabbit polyclonal anti-NF-B p65 antibodies were
obtained from Santa Cruz Biotechnology. The IgG-purified anti-OPN
antibody was purchased from R&D Systems. The anti-OPN antibody
was also raised against purified intact human OPN in rabbits and
characterized in our laboratory. Na125I (carrier-free; 3.7 GBq/ml) was
purchased from Board of Radiation and Isotope Technology (Mumbai,
India). Boyden-type cell migration chambers were obtained from Corn-
ing Corp. BioCoat MatrigelTM invasion chambers were from Collabora-
tive Biomedical. The nude mice (NMRI, nu/nu) were obtained from the
National Institute of Virology (Pune, India). All other chemicals were
analytical grade.
Cell Culture—The murine melanoma cells (B16F10) were obtained
from American Type Culture Collection (Manassas, VA). These cells
were cultured in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal calf serum, 100 units/ml penicillin, 100 g/ml strepto-
mycin, and 2 mM glutamine in a humidified atmosphere of 5% CO2 and
95% air at 37 °C.
Purification and Detection of OPN in Human Milk—Human milk
was collected from a local hospital. OPN was purified by DEAE-Seph-
adex chromatography, followed by FPLC. Briefly, the milk sample was
centrifuged, and the cleared sample was loaded onto the DEAE-Seph-
adex column. The column was washed with 10 mM sodium phosphate
buffer (pH 7.0) containing 100 mM NaCl and eluted with the same
buffer containing 500 mM NaCl. The fractions containing OPN were
analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) according
to Laemmli (22), followed by Western blot analysis. Briefly, the OPN
sample was resolved by SDS-PAGE and electrotransferred from the gel
to a nitrocellulose membrane. The membrane was incubated with es-
tablished IgG-purified anti-OPN antibody (1:5000 dilution). It was
washed, incubated further with horseradish peroxidase-conjugated an-
ti-rabbit IgG (1:2000 dilution), and detected using an ECL detection
system (Amersham Pharmacia Biotech). Partially purified OPN was
purified further on an FPLC Resource-Q column with a linear gradient
of 0–1 M NaCl in 20 mM Tris-HCl (pH 7.6) over a period of 40 min and
rechromatographed under the same conditions on the Resource-Q col-
umn. The final purity of OPN was checked by SDS gel and Western blot
analyses using both established and in-house anti-OPN antibodies as
described above. The concentration of OPN was measured by the Brad-
FIG. 1. Purification and characterization of OPN from human milk. A and B, shown are typical separation patterns of OPN in FPLC
Resource-Q chromatograms. OPN was partially purified from cleared human milk by DEAE-Sephadex chromatography. The partially purified
samples were purified further on an FPLC Resource-Q column with a linear gradient of 0–1 M NaCl in 20 mM Tris-HCl (pH 7.6) over a period of
40 min (A). The fraction containing OPN was rechromatographed on an FPLC Resource-Q column (B). C, the purity of OPN was checked by
SDS-PAGE, followed by Coomassie Blue staining (panel a). The purified protein was further characterized by Western blot analysis using in-house
rabbit anti-OPN antibody (panel b) and established commercially available goat IgG-purified anti-OPN antibody (panel c).
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ford method (Bio-Rad protein assay) according to the manufacturer’s
instructions.
Zymography Experiments—To check the effect of OPN on MMP-2
expression and activation, the B16F10 cells were treated with varying
concentrations of purified OPN (0–10.0 M) in serum-free medium and
incubated at 37 °C for 24 h. The conditioned media were collected by
centrifugation, concentrated, and dialyzed. The dialyzed samples con-
taining an equal amount of total proteins were mixed with sample
buffer in the absence of reducing agent, incubated at room temperature
for 30 min, and loaded onto zymographic SDS gel containing gelatin (0.5
mg/ml) as described (23). The gels were washed and incubated in
incubation buffer (50 mM Tris-HCl (pH 7.5) containing 100 mM CaCl2, 1
M ZnCl2, 1% (v/v) Triton X-100, and 0.02% (w/v) NaN3) for 16 h. The
gels were stained with Coomassie Blue and destained. The zones of
gelatinolytic activity were shown by negative staining. Purified MMP-2
was used as a control. In separate experiments, the cells were treated
with other ECM proteins (5.0 M each fibronectin, type I collagen, or
laminin) or peptides (10.0 M each GRGDSP, GPenGRGDSPCA, or
GRGESP) and incubated under the same conditions described above.
The conditioned media were collected and used for zymography.
Northern Blot Analysis—To analyze the levels of MMP-2 and TIMP-2
mRNAs in untreated and OPN-treated cells, the cells were first treated
with OPN (10 M), and total RNA was extracted using the RNAzol
method (Tel-Test) according to the manufacturer’s instructions. RNA
concentration was measured spectrophotometrically at absorbances of
260 and 280 nm. An equal amount of total RNA (20 g) was denatured
in formaldehyde and resolved by electrophoresis on formaldehyde-aga-
rose gels. The RNA samples were transferred from the gels to nylon
membranes and cross-linked by UV irradiation. Hybridization was
performed using an -32P-labeled mouse MMP-2 or TIMP-2 probe. The
708-base pair MMP-2 cDNA probe was obtained by polymerase chain
reaction amplification, followed by hybridization with an MMP-2-spe-
cific probe. The 508-base pair TIMP-2 probe was obtained by digesting
plasmid pBluescript SK containing partial-length TIMP-2 cDNA (nu-
cleotides 1173–1680) (a generous gift from Prof. M. Seiki, University of
Tokyo, Tokyo, Japan) with HindIII. The DNA was purified by agarose
gel electrophoresis. The probe was labeled with [-32P]dCTP using a
random primer labeling kit (Bangalore Genei, Bangalore, India) accord-
ing to the manufacturer’s instructions. The blots were exposed to East-
man Kodak X-Omat AR x-ray film and autoradiographed.
Nuclear and Cytoplasmic Extracts, Transfection, and Western Blot-
ting—The nuclear extracts were prepared using a modification (24) of
the method of Dignam (40). Briefly, cells were incubated in the absence
or presence of OPN (5 M) in serum-free medium at 37 °C for 24 h. Cells
were scraped, washed with PBS, resuspended in hypotonic buffer (10
mM Hepes (pH 7.9), 10 mM MgCl2, 10 mM KCl, 0.2 mM phenylmethyl-
sulfonyl fluoride, and 0.5 mM dithiothreitol), and allowed to swell on ice
for 10 min. Cells were homogenized in a Dounce homogenizer. The
nuclei were separated by spinning at 3300  g for 5 min at 4 °C and
resuspended in low salt buffer (20 mM Hepes (pH 7.9), 25% glycerol, 1.5
mM MgCl2, 1.2 mM KCl, 0.2 mM EDTA, 0.2 mM phenylmethylsulfonyl
fluoride, and 0.5 mM dithiothreitol), followed by the addition of an equal
volume of high salt buffer. The lysed nuclei were centrifuged at
12,000 g for 5 min at 4 °C, and the cleared supernatant was collected.
The post-nuclear supernatant was used for cytoplasmic extraction. To
this supernatant was added 0.1 volume of cytoplasm extraction buffer
(0.3 mM Hepes (pH 7.9) containing 30 mM MgCl2 and 1.4 M KCl). The
sample was centrifuged, and the cleared supernatant was collected. The
protein concentrations in the supernatants of both nuclear and cyto-
plasmic extracts were measured by the Bio-Rad protein assay. The level
of NF-B p65 in both nuclear and cytoplasmic extracts was detected by
Western blot analysis using rabbit polyclonal anti-NF-B p65 antibody
as described above. In other experiments, the super-repressor form of
IB fused downstream to a FLAG epitope in an expression vector
FIG. 2. A, detection of MMP-2 expression in B16F10 cells by zymography. Panel a, the cells were treated in the absence or presence of OPN
(0–10.0 M); the conditioned media were collected; and MMP-2 activity was analyzed by gelatin zymography. Lane 1, purified MMP-2 as a
standard; lane 2, untreated cells; lanes 3, cells treated with 5 M OPN; lane 4, cells treated with 10 M OPN. The arrows indicate both 72- and
66-kDa MMP-2-specific bands. Panel b, the levels of MMP-2 (pro and active) were quantified by densitometric analysis. B, expression of MMP-2
mRNA by Northern blot analysis. Upper panel a, shown are the faint and intense MMP-2-specific mRNA bands in the untreated (lane 1) and
OPN-treated (lane 2) cells. Lower panel a, the rRNA bands are shown as a control. Panel b, RNA bands were quantified by densitometric analysis,
and the ratio of specific mRNA to rRNA is represented in the form of a bar graph. In both panels b, the mean values of three experiments are
calculated.
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(pCMV4) was transiently transfected into cells using LipofectAMINE
Plus reagent according to the manufacturer’s instructions. Briefly, the
vector containing IB was mixed with plus reagent in Opti-MEM I and
incubated at room temperature for 15 min. LipofectAMINE was mixed
with DNA plus reagent and incubated further at room temperature for
15 min. The LipofectAMINE Plus-DNA complex was added to cells and
mixed by gentle agitation. After 48 h, the cells were treated in the
absence or presence of OPN (5 M) and incubated further at 37 °C for
24 h. Cells were extracted with radioimmune precipitation assay buffer
(50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 1% Triton
X-100, 1% sodium deoxycholate, 0.1% SDS, 5 mM iodoacetamide, and 2
mM phenylmethylsulfonyl fluoride) at 4 °C for 2 h. The supernatant was
collected by centrifugation and used for detection of MT1-MMP by
Western blotting using mouse monoclonal anti-MT1-MMP antibody as
described above.
Cell Migration Assay—The migration assay was conducted using a
Transwell cell culture chamber according to the standard procedure
described (25). Briefly, the confluent monolayer of B16F10 cells was
harvested with trypsin/EDTA and centrifuged at 800  g for 10 min.
The cell suspension (5 105 cells/well) was added to the upper chamber
of a pre-hydrated polycarbonate membrane filter. Purified intact OPN
(0–10 M) was added to the upper chamber. The lower chamber was
filled with fibroblast-conditioned medium, which acted as a chemoat-
tractant. To ascertain whether OPN-stimulated migration occurred via
v3 integrin, the cells were pretreated with anti-human v3 integrin
antibody (40 g/ml) for 20 min, and then OPN was added (5.0 M).
Similarly, the cells were also pretreated with monoclonal anti-MMP-2
antibody (50.0 g/ml), and then OPN was added. In other experiments,
the cells were individually treated with GRGDSP, GRGESP, or GPen-
GRGDSPCA (5.0 M each) for 20 min and then incubated with OPN (5.0
M). After treatment, the cells were incubated in a humidified incubator
in 5% CO2 and 95% air at 37 °C for 24 h. The non-migrating cells on the
upper side of the filter were scraped and washed. The migrating cells on
the reverse side of the filter were stained with Giemsa. The migrating
cells on the filter were counted and a photomicrograph was taken under
an Olympus inverted microscope. In separate experiments, SMMP-2- or
ASMMP-2-transfected cells (5  105 cells/well) were added to the upper
chamber, and a migration assay was performed under the same condi-
tions as described above. The experiments were repeated in triplicate.
Preimmune IgG served as a nonspecific control.
ECM Invasion Assay—The ECM invasion assay was performed using
commercially available 24-well plates that consist of upper and lower
chambers as described (26, 27). The two chambers were divided by a
porous filter, the upper surface of which was precoated with a layer of
artificial basement membrane, MatrigelTM (Collaborative Biomedical).
The cell suspension (5  105 cells/well) was added to the upper cham-
ber. The lower chamber was filled with fibroblast-conditioned medium.
which acted as a chemoattractant. The cells were treated with varying
concentrations of purified intact OPN (0–10.0 M) and then added to
the upper chamber. In some experiments, the cells were pretreated with
anti-human v3 integrin antibody (40.0 g/ml), monoclonal anti-
MMP-2 antibody (50.0 g/ml), GRGDSP (5.0 M), GRGESP (5.0 M), or
GPenGRGDSPCA (5.0 M) for 20 min and then incubated with OPN
(5.0 M) at 37 °C for 24 h as described above. The non-migrating cells
and Matrigel from the upper side of the filter were scraped and removed
using a moist cotton swab. The invaded cells in the lower side of the
filter were stained with Giemsa and washed with PBS (pH 7.6). The
invaded cells were then counted, and photomicrographs were taken
under the Olympus inverted microscope. In other experiments,
SMMP-2- or ASMMP-2-transfected cells (5  105 cells/well) were added
to the upper chamber, and the invasion assay was done under the same
conditions as described above. The experiments were repeated in trip-
licate. Preimmune IgG was used as a nonspecific control.
Proliferation Assay—The proliferation assay was performed as de-
scribed previously (14). Briefly, serum-starved B16F10 cells were incu-
bated in the absence or presence of increasing concentrations of OPN
(0–10 M) at 37 °C for 24 h. After 4 h, [3H]thymidine (1 Ci/ml) was
added, and the cells were maintained in culture for another 20 h. After
removing the supernatants, the cells were washed with basal medium
and lysed in 50% trichloroacetic acid. The acid-precipitable cell-bound
radioactivity was measured with a scintillation counter (Packard In-
strument Co.).
Cell-surface Labeling—To detect the level of v3 integrin in B16F10
cells, the cells were surface-labeled with Na125I and IODO-BEADS as
described (28). The cells were lysed in lysis buffer composed of 1%
Triton X-100 solution containing 1 mM phenylmethylsulfonyl fluoride,
20 g/ml leupeptin, and 2 mM EDTA and immunoprecipitated individ-
ually with anti-human v or monoclonal anti-3 integrin antibody
(Roche Molecular Biochemicals) according to the manufacturer’s in-
structions. The samples were boiled in SDS sample buffer, electrophore-
sed, and autoradiographed.
Radioreceptor Assay—Purified human OPN (20 g) was radioiodi-
FIG. 3. A: expression of TIMP-2 mRNA by Northern blot analysis. Upper panel a, TIMP-2-specific mRNA bands are shown in lane 1 (untreated
cells) and lane 2 (OPN-treated cells). Lower panel a, rRNA bands are shown as a control. Note that there was an increase in TIMP-2 mRNA
expression in the OPN-treated cells. RNA bands were quantified by densitometric analysis, and the ratio of specific mRNA to rRNA is represented
in the form of a bar graph (panel b). These experiments were performed in triplicate, and the mean value was analyzed statistically. B: panel a,
effect of OPN on cellular localization of NF-B p65. Nuclear and cytoplasmic extracts from untreated and OPN-treated cells were immunoblotted
with rabbit polyclonal anti-NF-B p65 antibody (upper panel a). In the untreated cells, the majority of the p65 was detected in the cytoplasm, but
not in the nucleus (lanes 1 and 2, respectively). In contrast, upon OPN treatment, p65 was translocated from the cytoplasm to the nucleus (lanes
3 and 4, respectively). The relative intensity of p65 in the cytoplasm and nucleus was analyzed and is represented in the form of a bar graph (lower
panel a). Panel b, inhibition of OPN-induced MT1-MMP expression by the NF-B super-repressor IB. The cells were transfected with the
super-repressor form of IB in pCMV4 and then treated in the absence or presence of OPN. The cell lysates were used for the detection of
MT1-MMP by Western blot analysis (upper panel b). Lane 1, untreated non-transfected cells; lane 2, OPN-treated non-transfected cells; lane 3,
untreated transfected cells; lane 4, OPN-treated transfected cells. Note that there was an increase in MT1-MMP expression in OPN-treated cells
(lane 2) compared with control cells (lane 1), whereas in transfected cells, no differences in expression of MT1-MMP were observed in both
untreated (lane 3) and OPN-treated (lane 4) cells. The bands were analyzed by densitometry and are represented in the form of a bar graph (lower
panel b). The mean values of triplicate experiments are indicated in both lower panels a and b.
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nated using Na125I (carrier-free; 2 mCi) and chloramine T as described
(29). 125I-OPN was purified by Sephadex G-50 column chromatography,
and radioactivity was measured in a -counter (Beckman Instruments)
with a counting efficiency of 85%. The specific activity of carrier-free
purified monoiodinated OPN was 78 Ci/g. For binding assays, sub-
confluent cultures of B16F10 cells were incubated with 125I-OPN (3.0 
105 cpm/well) in the absence or presence of increasing concentrations of
unlabeled purified OPN in 1.0 ml of Hanks’ balanced salt solution (pH
7.6) containing 0.1% bovine serum albumin. After incubation at 37 °C
for 2 h, the reactions were stopped by rapid removal of medium con-
taining unbound radiolabeled OPN. The cells were solubilized with 1 N
NaOH and neutralized with 1 N HCl, and radioactivity was measured in
the -counter. Specific binding was calculated by subtracting nonspe-
cific binding from total binding. The Kd value was determined by
Scatchard analysis using the LIGAND computer program (30).
Oligonucleotide Treatments—Murine ASMMP-2 (5-CCA CTC GTG
CCT CCA TCG TT-3) and SMMP-2 (5-AAC GAT GGA GGC ACG
AGT-3) oligonucleotides with phosphorothioate linkages were synthe-
sized (Gemini Biotech). These oligonucleotides were purified by column
chromatography, and purity was checked by polyacrylamide gel elec-
trophoresis. The B16F10 cells were pretreated with OPN (10 M) at
37 °C for 6 h and then transfected transiently with the sense or anti-
sense S-oligonucleotide using LipofectAMINE Plus according to the
manufacturer’s instructions. Briefly, the sense or antisense S-oligonu-
cleotide was mixed with plus reagent, and then oligonucleotide reagent
plus was incubated with LipofectAMINE. The LipofectAMINE Plus-
oligonucleotide complex was added to the cells and incubated further at
37 °C for 8 h. The control cells received LipofectAMINE Plus alone. The
cell viability was detected by a trypan blue dye exclusion test. After
incubation, the oligonucleotide-containing medium was removed, and
the cells were refed with fresh medium and cultured for an additional
12 h. The serum-free conditioned medium was used for the detection of
MMP-2 by zymography, and the cells were used for migration, ECM
invasion, and tumorigenicity experiments as described above. To check
the dose-dependent response, a separate transfection experiment was
performed with different doses (0–10 g) of ASMMP-2.
In Vivo Tumorigenicity—The tumorigenicity experiments were per-
formed as described (31). The cells were grown in monolayer and
FIG. 4. Effect of OPN on cell migration (A), ECM invasion (B), and proliferation (C). A, the migration assay was performed using either
untreated cells (5  105 cells/well) or cells treated with three different concentrations of purified human OPN (2.5–10.0 M) in the upper chamber.
In separate experiments, the cells were pretreated individually with anti-v3 antibody (40 g/ml), GRGDSP (5.0 M), GRGESP (5.0 M), or
GPenGRGDSPCA (5.0 M) and then treated with OPN (5.0 M) in the upper chamber. The results are expressed as the means  S.E. of three
determinations. B, the ECM invasion assay was done using either untreated cells (5  105 cells/well) or cells treated with three different
concentrations of purified human OPN (2.5–10.0 M) in the upper chamber. In separate experiments, the cells were also pretreated with anti-v3
integrin antibody (40 g/ml), GRGDSP (5.0 M), GRGESP (5.0 M), or GPenGRGDSPCA (5.0 M) and then treated with OPN (5.0 M). The results
are expressed as the means  S.E. of three determinations. C, the proliferation assay was carried out by treating the cells with different doses of
OPN (1.25–10.0 M) in serum-free medium. The results are expressed as the means  S.E. of three determinations. In all three experiments,
preimmune IgG served as a control.
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treated in the absence or presence of purified human OPN (10 M) in
serum-free medium. The cells were incubated at 37 °C for 24 h. After
that, the cells (5 106 cells/0.2 ml) were detached, centrifuged, washed,
and injected subcutaneously into the flanks of male athymic NMRI
(nu/nu) mice (6–8 weeks old). Four mice were used in each set of
experiments. The mice were kept under specific pathogen-free condi-
tions. OPN (10 M) was again injected into the tumor sites twice a week
for up to 4 weeks. In other experiments, the cells were treated with OPN
(10 M) and injected into mice. A mixture (0.2 ml) of anti-MMP-2
antibody (50 g/ml) and OPN (10.0 M) was injected into the same
tumor sites twice a week for up to 4 weeks. In separate experiments, the
LipofectAMINE Plus-oligonucleotide (ASMMP-2 or SMMP-2) complex
was injected into the tumors of the nude mice. After 4 weeks, the mice
were killed, and the tumor weights were measured. The tumor tissues
were homogenized; lysed in lysis buffer composed of 50 mM Tris-HCl
(pH 7.5) containing 150 mM NaCl, 1% Nonidet P-40, 15 g/ml leupeptin,
and 0.5 mM phenylmethylsulfonyl fluoride; and centrifuged at 12,000 
g for 10 min. The clear supernatants were collected, and MMP-2 ex-
pression was detected by Western blot analysis (32). Briefly, the sample
containing an equal amount of total proteins was resolved by SDS-
PAGE. The protein was electrotransferred from the gel to a nitrocellu-
lose membrane. The membrane was incubated with mouse monoclonal
anti-MMP-2 antibody (1:250 dilution). It was washed, incubated further
with horseradish peroxidase-conjugated anti-mouse IgG (1:2000 dilu-
tion), and detected using the ECL detection system as described above.
The levels of MMP-2 in tumor samples were also analyzed by zymog-
raphy and Northern blot analysis as described above.
RESULTS
OPN Purification and Western Blot Analysis—Native OPN
was purified from human milk by DEAE-Sephadex chromatog-
raphy, followed by final purification on an FPLC Resource-Q
column. The cleared milk sample was passed through a DEAE-
Sephadex column. The protein sample was eluted with 10 mM
sodium phosphate buffer (pH 7.0) containing 500 mM NaCl. The
presence of OPN was checked by SDS-PAGE, followed by West-
ern blot analysis using both in-house and established anti-OPN
antibodies. The major fraction containing OPN was rechro-
matographed on an FPLC Resource-Q column, and the chro-
matogram is shown in Fig. 1A. Of six fractions in Fig. 1A,
fraction 3 showed the OPN-specific band as judged by SDS-
PAGE and Western blot analysis (data not shown). Fraction 3
was rechromatographed using a Resource-Q column and
showed a major single symmetrical peak (Fig. 1B). The concen-
tration of OPN was measured by the Bio-Rad protein assay.
The final purity of OPN was checked by SDS-PAGE, followed
by Coomassie Blue staining (Fig. 1C, panel a), and further
characterized by Western blot analysis using rabbit anti-OPN
(panel b) and established goat IgG-purified anti-OPN (panel c)
antibodies.
OPN Induces MMP-2 Expression at the Protein and mRNA
Levels—To check the effect of OPN on pro-MMP-2 production
and activation, the B16F10 cells were treated with increasing
concentrations of OPN (0–10.0 M). The conditioned media
were collected, and the gelatinolytic activity of MMP-2 was
detected by zymography. Increased levels of MMP-2 expression
(72-kDa pro and 66-kDa active forms) were observed when the
cells were treated with two different concentrations of OPN
(Fig. 2A, panel a, lanes 3 and 4). Minor bands of pro-MMP-2
and active MMP-2 were detected in the untreated cells (lane 2).
Purified MMP-2 was used as a positive control (lane 1). The
levels of active MMP-2 and pro-MMP-2 expression (gelatino-
lytic activity) were quantified densitometrically (Kodak Digital
Science) and analyzed statistically. As compared with controls,
there were at least 5- and 9.8-fold increases in MMP-2 activa-
tion when the cells were treated with 5.0 and 10.0 M OPN,
respectively (panel b). To ascertain the specificity of induction
of MMP-2 expression, the cells were individually treated with
fibronectin, type I collagen, laminin, GRGDSP, GPenGRGD-
SPCA, or GRGESP prior to zymography. No significant levels
of MMP-2 expression were observed by zymography (data not
shown).
The OPN-induced MMP-2 expression in these cells was re-
confirmed by Northern blot analysis. The intensity of the
MMP-2-specific band was increased when the cells were
treated with 10 M OPN (Fig. 2B, upper panel a, lane 2).
However, a minor MMP-2-specific band was observed in the
untreated cells (lane 1). The low level of MMP-2 mRNA expres-
sion in the untreated cells was not due to degradation of RNA
because strong bands of rRNA were obtained, a result that was
virtually identical in each of the untreated and OPN-treated
samples (lower panel a). The level of MMP-2 mRNA was also
quantified by densitometry and analyzed statistically. There
was at least a 2.8-fold increase in MMP-2 mRNA expression in
OPN-treated cells compared with control cells (panel b). These
data were corroborated by the zymography data (Fig. 2A).
OPN Induces MT1-MMP Expression by Activating NF-B—
Since the mechanism for activation of pro-MMP-2 involves
complex formation with MT1-MMP and TIMP-2, we sought to
FIG. 5. A, cell-surface labeling of v3 integrin in B16F10 cells. The
cells were labeled with Na125I, individually immunoprecipitated with
anti-v (upper panel) or anti-3 (lower panel) integrin antibody, resolved
by SDS-PAGE, and autoradiographed. B, binding of OPN to its receptor
in B16F10 cells. 125I-OPN was incubated with B16F10 cells in the
absence or presence of increasing concentration of unlabeled OPN (0–
5.0 g/ml) at 37 °C for 2 h. The data are from three experiments, and
each point represents the mean of triplicate determinations.
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determine whether OPN has any role in MT1-MMP expression.
The Western blot analysis data indicated that the level of
MT1-MMP expression (58 kDa) was 1.5 times higher in OPN-
treated cells than in untreated cells (Fig. 3B, upper panel b,
lanes 1 and 2, respectively). Since it has been previously shown
that OPN stimulates NF-B signaling by interacting with v3
integrin in endothelial cells (33), we therefore speculated that
NF-B might be involved in OPN-induced MMP-2 activation in
B16F10 cells. Our Western blot data revealed that p65 was
localized mostly in the cytoplasm (upper panel a, lane 1) com-
pared with the nucleus (lane 2) in the OPN-untreated cells.
However, it was translocated from the cytoplasm (lane 3) to the
nucleus (lane 4) in the OPN-treated cells. The Western blot
data were further quantified by densitometric statistical anal-
yses (lower panel a).
To check whether OPN-induced MT1-MMP expression oc-
curs through the NF-B/IB pathways, we transiently trans-
fected the cells with the super-repressor form of IB and then
treated them with OPN. The expression of MT1-MMP in un-
treated and OPN-treated cells was almost identical (Fig. 3B,
upper panel b, lanes 3 and 4). These Western blot data were
also analyzed (lower panel b). These results suggest that OPN
activates the NF-B signaling pathway, leading to induction of
MT1-MMP and subsequently activating pro-MMP-2.
OPN Stimulates TIMP-2 Expression in B16F10 Cells—To
determine whether OPN has any role in induction of TIMP-2
expression in B16F10 cells, the RNA was isolated from the
untreated and OPN-treated cells, and expression of TIMP-2
was analyzed by Northern blot analysis. The level of TIMP-2
expression was increased in the OPN-treated cells (Fig. 3A,
upper panel a, lane 2), but the level of TIMP-2 expression was
lower in the untreated cells (lane 1). The rRNA bands are
FIG. 6. A, detection of MMP-2 expression in MMP-2-specific S-oligonucleotide-transfected cells by zymography. Panel a, cells were pretreated
with OPN and then transfected with LipofectAMINE Plus alone (lane 1) or with SMMP-2 (lane 2) or ASMMP-2 (lane 3). The conditioned media
were collected and used for zymography. The arrows indicate the 72-kDa (pro) and 66-kDa (active) MMP-2 bands. Panel b, the levels of MMP-2
were quantified by densitometric analysis and are represented in the form of a bar graph. The mean value of triplicate experiments is indicated.
B, effect of transfection of OPN-treated B16F10 cells with MMP-2-specific S-oligonucleotide on cell migration. Cells were pretreated with OPN and
then transfected with LipofectAMINE Plus alone or with SMMP-2 or ASMMP-2 as described above. Both non-transfected and transfected cells
were used for the cell migration assay as described under “Experimental Procedures.” The cells transfected with ASMMP-2 showed dramatic
reduction of cell migration compared with non-transfected cells or cells transfected with LipofectAMINE Plus alone or with SMMP-2. The results
are expressed as the means  S.E. of three determinations. C, effect of transfection of OPN-treated cells with MMP-2 specific S-oligonucleotide on
ECM invasion. Cells were pretreated with OPN, transfected, and then used for the ECM invasion assay as described above. The cells transfected
with ASMMP-2 showed dramatic reduction of invasion compared with non-transfected cells or cells transfected with LipofectAMINE Plus alone
or with SMMP-2. The results are expressed as the means  S.E. of three determinations.
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shown as a control (lower panel a, lanes 1 and 2). The densito-
metric data indicated that there was a slight increase in
TIMP-2 expression in the OPN-treated cells, whereas the un-
treated cells expressed low levels of TIMP-2 (panel b).
OPN Enhances in Vitro Cell Migration, ECM Invasion, and
Cell Proliferation—To examine the effect of OPN on B16F10
cells, we used established in vitro assay systems to evaluate the
effects of this protein on cell migration, ECM invasion, and
proliferation. Fig. 4A shows the dose-dependent increases in
cell migration (123–239%) when increasing concentrations of
OPN (2.5–10.0 M) were used in the upper chamber. The OPN-
untreated cells are used as controls (100% migration). Inter-
estingly, the OPN-induced migration was drastically reduced
when the cells were pretreated individually with anti-human
v3 integrin antibody, GRGDSP, or GPenGRGDSPCA (but
not with GRGESP) prior to the addition of OPN (Fig. 4A).
Similarly, there was a dramatic increase in ECM invasion
(114–219%) when the cells were pretreated with increasing
concentrations of OPN (2.5–10 M), as shown in Fig. 4B. The
OPN-untreated cells were used as controls (100% invasion).
The OPN-induced ECM invasion was also suppressed when the
cells were individually pretreated with anti-human v3 inte-
grin antibody, GRGDSP, or GPenGRGDSPCA (but not with
GRGESP) prior to the addition of OPN (Fig. 4B). These data
indicate that OPN-induced migration and ECM invasion occur
through interaction with the OPN receptor (v3 integrin) and
that the RGD sequence of OPN is involved in both of these
processes. When preimmune IgG used in the upper chamber,
no migration and ECM invasion were observed, suggesting that
the migration and ECM invasion of melanoma cells are OPN-
specific (data not shown). To examine whether OPN has any
role in the growth rate of these cells, we performed the prolif-
eration assay by treating the cells with different doses of OPN
(0–10 M). The results indicate that OPN induces cell growth
(121–198%) in a dose-dependent manner in these cells (Fig.
4C).
Characterization of the v3 Integrin Receptor—Because
OPN induces cell migration and ECM invasion by interacting
with v3 integrin, we sought to determine whether these cells
express any functional v3 integrin receptor. Accordingly, the
cells were surface-labeled with Na125I and immunoprecipitated
individually with anti-v or anti-3 integrin antibody. The im-
munoprecipitated complex was resolved by SDS-PAGE and
autoradiographed. Fig. 5A represent the v (upper panel) and
3 (lower panel) integrin expression in these cells. In addition,
we performed the displacement binding experiments using ra-
diolabeled OPN as a ligand. The binding data were analyzed by
the LIGAND computer program, and the results indicate that
OPN binds to its receptor with high affinity and specificity,
with a Kd of 1.1 nM (Fig. 5B).
MMP-2 Plays a Crucial Role in in Vitro Cell Migration and
ECM Invasion—To assess the direct role of MMP-2 in cell
migration and ECM invasion, the OPN-treated cells were tran-
siently transfected with LipofectAMINE Plus containing
SMMP-2 or ASMMP-2 with phosphorothioate linkage. The con-
ditioned media were collected after transfection, and the level
of MMP-2 was analyzed by zymography. Both latent and active
MMP-2 expression was reduced when the cells were trans-
fected with ASMMP-2 (Fig. 6A, panel a, lane 3), but MMP-2
expression remained the same in cells transfected with Lipo-
fectAMINE Plus (lane 1) or SMMP-2 (lane 2). The data were
also quantified by densitometric analysis (panel b). The trans-
fected cells were also used for cell migration (Fig. 6B) and ECM
invasion (Fig. 6C) assays. The migration of non-transfected
cells treated with 10.0 M OPN was considered to be 100%
(control). There was a dramatic suppression of OPN-induced
migration (49%) when ASMMP-2-transfected cells were used,
but no significant differences were observed in LipofectAMINE
Plus- or SMMP-2-transfected cells (Fig. 6B). Similarly, a dra-
matic reduction of OPN-induced invasion (44%) was observed
in ASMMP-2-transfected cells, but no significant changes were
noted in LipofectAMINE Plus- or SMMP-2-transfected cells
(Fig. 6C). These results demonstrate that MMP-2 plays a crit-
ical role in OPN-induced cell migration and ECM invasion.
Tumorigenicity Experiments—The in vitro results prompted
us to examine whether OPN has any role in tumor growth and
regulating the expression of MMP-2 in an in vivo system.
Accordingly, B16F10 cells were treated with OPN (10.0 M)
and then injected subcutaneously into the flanks of nude mice.
Fig. 7A (panels a–c) shows typical photographs of tumors
grown in 4-week-old nude mice. After 4 weeks, the mice were
killed, and tumor weights was measured. The weights of the
OPN-induced tumors were increased at least 3.1-fold compared
with the tumors of the non-OPN-injected mice (Table I). How-
FIG. 7. A, typical photographs of OPN-induced tumors in nude mice.
The B16F10 cells were treated in the absence or presence of OPN (10.0
M) and injected subcutaneously into the flanks of nude mice. In sep-
arate experiments, the OPN-treated cells were injected into the nude
mice, and then anti-MMP-2 antibody (10.0 g/0.2 ml) was injected into
the tumor sites. Four mice were used in each set of experiments. Panel
a, cells with PBS; panel b, cells with OPN; panel c, cells with OPN and
anti-MMP-2 antibody. B, detection of MMP-2 expression in the tumors
of nude mice by gelatin zymography (panel a) and Western blotting
(panel b). Panel a, the tumor samples from A were lysed in lysis buffer
and analyzed by gelatin zymography. Equal amount of total proteins
was used in each lane. Lane 1, PBS alone; lane 2, with OPN; lane 3, with
OPN and anti-MMP-2 antibody. The arrows indicate the 72- and 66
kDa-MMP-2-specific bands. Panel b, the tumor samples from A were
lysed. Equal amounts of total proteins were electrophoresed and trans-
ferred to the nitrocellulose membranes. The membranes were immuno-
stained with mouse monoclonal anti-MMP-2 antibody and detected by
ECL detection system as described under “Experimental Procedures.”
Lane 1, PBS alone; lane 2, with OPN.
OPN Modulates MMP-2 Activation and Tumor Growth 44933
 by guest, on O
ctober 27, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
ever, the weights of the OPN-induced tumors were reduced
dramatically when anti-MMP-2 antibody was injected into the
sites of the tumors (Table I). Four mice were used in each set of
experiments. To detect the levels of pro-MMP-2 and active
MMP-2 expression in the tumors, the samples were lysed, and
MMP-2 expression was analyzed by zymography (Fig. 7B,
panel a). The levels of both the pro and active forms of MMP-2
in the tumors produced by OPN (10.0 M) were significantly
higher (panel a, lane 2) compared with the levels of MMP-2 in
the tumors in non-OPN-injected mice (lane 1). However, the
levels of MMP-2 (especially the active form) were reduced sig-
nificantly in the anti-MMP-2 antibody-injected mice (lane 3).
MMP-2 expression in tumors was further confirmed by West-
ern blot analysis (panel b). Both latent and active MMP-2
expression was much higher in the tumors of the OPN-injected
mice (lane 2) than in the tumors of the control mice (lane 1),
and these data were corroborated by the zymography data
(panel a). Moreover, MMP-2 mRNA expression in tumors was
analyzed by Northern blot analysis, and it appeared that the
level of mRNA expression was also significantly higher in the
tumors of the OPN-injected mice compared with those of the
control mice (data not shown). Taken together, these data
strongly suggest that OPN-induced MMP-2 (both latent and
active) expression in tumors occurs at both the transcriptional
and post-transcriptional levels, and these values correlate with
tumor growth (melanoma formation) in nude mice. Moreover,
the data also demonstrate that when ASMMP-2-transfected
cells were injected into mice, the size of the tumors was reduced
drastically (Fig. 8c) compared with LipofectAMINE Plus-in-
jected (Fig. 8a) or SMMP-2-injected (Fig. 8b) mice. The -fold
changes in tumor weight caused by injection with Lipo-
fectAMINE Plus or different S-oligonucleotides are shown in
Table II. The tumor weights of ASMMP-2-injected mice were
reduced to one-third of the tumor weights of LipofectAMINE-
or SMMP-2-injected mice (Table II). Four mice were used in
each set of experiments. The expression levels of pro-MMP-2
and active MMP-2 in ASMMP-2-injected mice were much lower
than in LipofectAMINE Plus- or SMMP-2-injected mice as de-
tected by zymography and Western blot analysis (data not
shown).
DISCUSSION
Signals transduced by cell adhesion molecules play an im-
portant role in tumor cell attachment, motility, and invasion,
all of which are key steps in the process of tumor metastasis.
Cell-matrix interactions play a major role in tissue remodeling,
cell survival, and tumorigenesis. OPN, an extracellular matrix
protein, plays a significant role in cell adhesion, migration, and
metastasis. It has been shown that overexpression of OPN is
associated with various cancers and their metastatic potentials
(12). MMPs are a family of Zn2-dependent endopeptidases
that are responsible for remodeling of the extracellular matrix
and degradation of ECM proteins. Several studies have shown
the correlation between MMP-2 expression and metastatic po-
tential and suggested that MMP-2 may act as a useful marker
for the prognosis or diagnosis of cancers (34, 35). Therefore, we
sought to determine whether OPN has any role(s) in the regu-
lation of MMP-2 activation and control of cell motility, inva-
siveness, and tumor growth using B16F10 cells.
We have demonstrated that purified intact human OPN in-
duces pro-MMP-2 production and activation in a dose-depend-
ent manner in these cells. However, other ECM proteins such
as fibronectin, type I collagen, laminin, and RGD-containing
non-cyclic or cyclic peptides (GRGDSP and GPenGRGDSPCA)
are unable to induce MMP-2 production and activation. Since
OPN induces MMP-2 activation, we investigated whether OPN
enhances cell migration and ECM invasion in B16F10 cells.
The results indicate that OPN enhances cell migration and
ECM invasion in a dose-dependent manner. Previous reports
have shown that vitronectin induces MMP-2 and TIMP-2 se-
cretion and enhances invasiveness in B16F1 and B16F10 cells
(19). Maquoi et al. (21) demonstrated that type IV collagen
induces MMP-2 activation in human fibrosarcoma cells. These
data are supported by our present findings demonstrating di-
rect dose-dependent increases in MMP-2 activation, cell migra-
tion, and ECM invasion by OPN in B16F10 cells. We also found
that pretreatment of cells with anti-v3 integrin antibody
blocked OPN-induced cell migration and ECM invasion, sug-
gesting that OPN-enhanced cellular responses occur through
interaction with the v3 integrin receptor. Therefore, we an-
alyzed whether these cells express any functional v3 integrin
receptor. Cell-surface labeling and immunoprecipitation with
anti-v and anti-3 integrin antibodies showed that these cells
express v3 integrin. Binding data revealed that radiolabeled
OPN interacts with its receptor with high affinity (Kd 1.1 nM)
and specificity. The OPN-derived RGD-containing peptides
TABLE I
Effect of OPN and anti-MMP-2 antibody on tumor growth
B16F10 cells were treated with OPN and injected into nude mice
(NMRI). In separate experiments anti-MMP-2 antibody (Ab) was in-
jected into the OPN-induced tumor sites. The injections were performed
twice a week for 4 weeks. The mice were killed, and the tumor weights
were measured and analyzed statistically by Student’s t test (p 
0.005). Mice injected with cells in PBS were used as controls.
No. nude mice Treatment Tumor wt (-fold changes)
Four Control (PBS) 1.0  0.25
Four OPN 3.1  0.15
Four OPN and anti-MMP-2 Ab 0.93  0.1
FIG. 8. Typical photographs of MMP-2-specific S-oligonucleo-
tide-injected tumors in nude mice. The cells were treated with OPN
and transfected with LipofectAMINE Plus containing SMMP-2 or
ASMMP-2. The transfected cells were injected into the nude mice. Four
mice were used in each set of experiments. Panel a, LipofectAMINE
Plus; panel b, LipofectAMINE Plus and SMMP-2; panel c, Lipo-
fectAMINE Plus and ASMMP-2.
TABLE II
Effect of MMP-2-specific S-oligonucleotides on tumor growth
The cells were treated with OPN, transfected with LipofectAMINE
Plus containing SMMP-2 or ASMMP-2, and then injected into nude
mice. The LipofectAMINE Plus-oligonucleotide complex was injected
into the tumor sites in the nude mice twice a week for 4 weeks. The mice
were killed, and the tumor weights were measured and analyzed sta-
tistically by Student’s t test (p  0.007). The LipofectAMINE Plus-
injected mice were used as controls.
No. nude mice Transfected cells Tumor wt (-fold changes)
Four LipofectAMINE Plus 1.0  0.05
Four SMMP-2 0.95  0.1
Four ASMMP-2 0.37  0.02
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(GRGDSP and GPenGRGDSPCA) suppressed OPN-enhanced
cell migration and ECM invasion.
Transfection data showed that OPN-induced MMP-2 produc-
tion can be regulated at the transcriptional level, resulting in
lower OPN-enhanced cell migration and ECM invasion These
data clearly demonstrate that MMP-2 is required in these
cellular processes. Similarly, pretreatment of cells with anti-
MMP-2 antibody blocked MMP-2 activation and thereby re-
duced OPN-induced migration and invasion (data not shown).
To determine the function of OPN in tumor growth and to
check the status of MMP-2 in OPN-induced tumors, several
experimental approaches were used. These include the tumor
growth assay and specific inhibition of tumor growth by anti-
MMP-2 antibody and ASMMP-2. OPN-induced tumor growth
was suppressed by anti-MMP-2 antibody or ASMMP-2, sug-
gesting that MMP-2 contributes to tumor growth. Proliferation
data indicated that OPN stimulates the growth rate in B16F10
cells, and these data may partly explain the OPN-induced
tumor growth in nude mice. Gardner et al. (36) have shown that
antisense OPN expression in transformed malignant rat fibro-
blasts correlates with decreases in tumor growth, and these
data support our experimental results. The levels of pro-
MMP-2 and active MMP-2 in OPN-induced tumors were sig-
nificantly higher than in controls. Moreover, the level of active
MMP-2 in tumors was reduced dramatically in anti-MMP-2
antibody-injected mice. This reduction is probably due to anti-
MMP-2 antibody blockage of the activation of MMP-2 by inhib-
iting the activation pathways. It has been shown previously
that the localization of active MMP-2 to the cell surface by
binding to v3 integrin is essential for tumor growth (37, 38).
It is possible that anti-MMP-2 antibody may block the active
MMP-2 that is available for binding to the cell surface, thereby
reducing tumor growth.
We have delineated for the first time the biochemical mech-
anism by which OPN induces cell migration, ECM invasion,
and tumorigenicity by inducing MMP-2 expression and activa-
tion. Activation is necessary for the functional consequence of
MMP-2 expression. Activation of MMP-2 requires its cell-sur-
face localization and cleavage by cell membrane-bound MT1-
MMP. TIMP-2 is involved in this process by forming a receptor
for pro-MMP-2 (39). We have detected an increased level of
TIMP-2 expression in OPN-treated B16F10 cells. The balance
between TIMP-2 and MMP-2 levels is critical in determining
the activation status of MMP-2 because overexpression of
TIMP-2 would lead to MMP-2 inhibition. We have also detected
increased levels of MT1-MMP expression by Western blot anal-
ysis. Increased pro-MMP-2 activation reflects up-regulation of
MT1-MMP expression in OPN-treated cells, implying that
OPN facilitates a shift in balance toward increasing proteolytic
activity of MMP-2. The mechanism by which OPN activates
MMP-2 by inducing ternary complex formation is not well
understood. We observed that increased expression of MT1-
MMP by OPN correlates with translocation of NF-B into the
nucleus. Moreover, the NF-B super-repressor blocked OPN-
induced MT1-MMP expression, suggesting that OPN-stimu-
lated pro-MMP-2 activation is mediated by activation of
NF-B.
In summary, we have demonstrated for the first time that
native purified human OPN induces in vivo tumor growth and
stimulates in vitro cell migration and ECM invasion using
B16F10 cells. Moreover, increased invasiveness and tumor
growth correlate with enhanced expression of pro-MMP-2 and
active MMP-2 both in vivo and in vitro. We provide evidence
showing that OPN increases the gelatinolytic activity by induc-
ing MT1-MMP expression through the NF-B pathways. Fur-
thermore, the suppression of MMP-2 gene expression by
ASMMP-2 reduces the OPN-induced cell migration and ECM
invasion in these cells. Blocking the functional activity of
MMP-2 by its specific antibody also abrogates cell migration
and ECM invasion. Both the tumor size and MMP-2 production
and activation in OPN-induced tumors were abruptly reduced
when anti-MMP-2 antibody- or ASMMP-2-treated cells were
injected into the nude mice, and these data further support our
in vitro data. Finally, these data indicate that MMP-2 plays an
important role in OPN-enhanced cell migration, ECM invasion,
and tumor growth and further demonstrate that OPN-induced
activation of MMP-2 occurs via NF-B-mediated pathways.
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